Antidesmone
Antidesmone is a isoquinoline alkaloid that can be isolated from Antidesma membranaceum. Antidesmone can prevent acute lung injury in vivo via inhibiting MAPK and NF-κb activities.
For research use only. We do not sell to patients.
- CAS No.: 222629-77-8
- Formula: C19H29NO3
- Molecular Weight:319.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
8.4 μM
Compound: 8
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 32946697] |
| HeLa | IC50 |
23.4 μg/mL
Compound: 13
|
Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 26848627] |
| KB | IC50 |
17.7 μM
Compound: 8
|
Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 32946697] |
| L6 | IC50 |
184.3 μM
Compound: 10
|
Cytotoxicity against rat L6 cells
Cytotoxicity against rat L6 cells
|
[PMID: 25314007] |
| MCF7 | IC50 |
6.4 μM
Compound: 8
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 32946697] |
| MDA-MB-231 | IC50 |
6.7 μM
Compound: 8
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 32946697] |
| RAW264.7 | IC50 |
16.1 μM
Compound: 18
|
Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells preincubated for 15 mins followed by LPS stimulation and measured after 20 hrs by Griess reagent based assay
Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells preincubated for 15 mins followed by LPS stimulation and measured after 20 hrs by Griess reagent based assay
|
[PMID: 36746775] |
Chemical Information
-
CAS No. 222629-77-8
-
Molecular Weight 319.44
-
Formula C19H29NO3
-
SMILES
O=C1C(OC)=C(C)NC2=C1[C@@H](CCCCCCCC)CCC2=O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Antidesmone Related Classifications
HY-119731 Related Classifications
Powered by Bioz